Results 21 to 30 of about 319,900 (371)

Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.

Journal of the American Medical Association (JAMA), 2021
Importance Pregnant women are at increased risk of morbidity and mortality from COVID-19 but have been excluded from the phase 3 COVID-19 vaccine trials. Data on vaccine safety and immunogenicity in these populations are therefore limited. Objective To
Ai-ris Y. Collier, K. McMahan, Jingyou Yu, Lisa H. Tostanoski, R. Aguayo, J. Ansel, A. Chandrashekar, Shivani Patel, Esther Apraku Bondzie, D. Sellers, J. Barrett, O. Sanborn, H. Wan, A. Chang, T. Anioke, Joseph P. Nkolola, C. Bradshaw, C. Jacob-Dolan, J. Feldman, M. Gebre, E. Borducchi, Jinyan Liu, A. Schmidt, T. Suscovich, C. Linde, G. Alter, M. Hacker, D. Barouch   +27 more
semanticscholar   +1 more source

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

Nature Network Boston, 2021
Heterologous priming with the ChAdOx1 nCoV-19 vector vaccine followed by boosting with a messenger RNA vaccine (BNT162b2 or mRNA-1273) is currently recommended in Germany, although data on immunogenicity and reactogenicity are not available.
T. Schmidt, V. Klemis, D. Schub, J. Mihm, F. Hielscher, Stefanie Marx, A. Abu-Omar, L. Ziegler, C. Guckelmus, R. Urschel, S. Schneitler, S. Becker, B. Gärtner, U. Sester, M. Sester   +14 more
semanticscholar   +1 more source

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

New England Journal of Medicine, 2020
Background Testing of vaccine candidates to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased incidences of illness and death from coronavirus disease 2019 (Covid-19 ...
E. Anderson, N. Rouphael, A. Widge, L. Jackson, P. Roberts, M. Makhene, J. Chappell, M. Denison, Laura J. Stevens, A. Pruijssers, A. McDermott, B. Flach, Bob C. Lin, N. Doria-Rose, S. O'dell, S. Schmidt, Kizzmekia S. Corbett, P. Swanson, M. Padilla, K. Neuzil, H. Bennett, B. Leav, M. Makowski, J. Albert, Kaitlyn A. Cross, V. Edara, K. Floyd, M. Suthar, David R. Martinez, R. Baric, Wendy L. Buchanan, C. Luke, Varun K. Phadke, C. Rostad, J. Ledgerwood, B. Graham, J. Beigel   +36 more
semanticscholar   +1 more source

10th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals

mAbs, 2020
Therapeutic proteins and emerging gene and cell-based therapies are attractive therapeutic tools for addressing unmet medical needs or when earlier conventional treatment approaches failed.
S. Tourdot, A. Abdolzade-Bavil, J. Bessa, P. Broët, A. Fogdell-Hahn, M. Giorgi, V. Jawa, K. Kuranda, N. Legrand, S. Pattijn, J. A. Pedras-Vasconcelos, A. Rudy, P. Salmikangas, D. W. Scott, V. Snoeck, N. Smith, S. Spindeldreher, D. Kramer   +17 more
doaj   +1 more source

Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2021
The BNT162b2 mRNA COVID-19 vaccine showed high efficacy in clinical trials but observational data from populations not included in trials are needed. We describe immunogenicity 21 days post-dose 1 among 514 Israeli healthcare workers by age, ethnicity ...
K. Abu Jabal, H. Ben-Amram, K. Beiruti, Yunis Batheesh, Christian Sussan, S. Zarka, M. Edelstein   +6 more
semanticscholar   +1 more source

Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers

Journal of Nanobiotechnology, 2021
Virus-like particles (VLPs) are virus-derived structures made up of one or more different molecules with the ability to self-assemble, mimicking the form and size of a virus particle but lacking the genetic material so they are not capable of infecting ...
Saghi Nooraei, Howra Bahrulolum, Zakieh Sadat Hoseini, C. Katalani, A. Hajizade, A. Easton, G. Ahmadian   +6 more
semanticscholar   +1 more source

Learn–confirm in model‐informed drug development: Assessing an immunogenicity quantitative systems pharmacology platform

CPT: Pharmacometrics & Systems Pharmacology, 2023
Immunogenicity against therapeutic proteins frequently causes attrition owing to its potential impact on pharmacokinetics, pharmacodynamics, efficacy, and safety.
Linnea C. Franssen, Maciej J. Swat, Andrzej M. Kierzek, Rachel H. Rose, Piet H. van derGraaf, Hans Peter Grimm   +5 more
doaj   +1 more source

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

Nature Communications, 2021
The COVID-19 pandemic continues to spread throughout the world with an urgent need for a safe and protective vaccine to effectuate herd protection and control the spread of SARS-CoV-2.
Jing-hui Tian, N. Patel, Robert E. Haupt, Haixia Zhou, S. Weston, Holly Hammond, James Logue, Alyse D. Portnoff, James Norton, M. Guebre‐Xabier, Bin Zhou, K. Jacobson, Sonia Maciejewski, Rafia Khatoon, Małgorzata Wiśniewska, Will Moffitt, S. Kluepfel-Stahl, Betty Ekechukwu, James F. Papin, S. Boddapati, C. Jason Wong, P. Piedra, M. Frieman, M. Massare, L. Fries, K. Bengtsson, Linda Stertman, L. Ellingsworth, G. Glenn, Gale Smith   +29 more
semanticscholar   +1 more source

Trastuzumab immunogenicity development in patients’ sera and in laboratory animals

BMC Immunology, 2021
Background Immunogenicity is a major challenge in drug development and patient care. Clinicians and regulators are familiar with immunogenicity concerns of monoclonal antibody (mAb) therapeutics, growth factors and enzyme replacements.
Lobna Abdel Aziz Kilany, Ayman Abdel Samie Gaber, Mohammad Mabrouk Aboulwafa, Hamdallah Hafez Zedan   +3 more
doaj   +1 more source

Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2

Annals of Internal Medicine, 2021
Evidence suggests that immunogenicity to mRNA-based SARS-CoV-2 vaccination in immunosuppressed patients may be reduced. This study assessed the response to 2 doses of mRNA-based SARS-CoV-2 vaccine among 133 participants with underlying chronic ...
P. Deepak, Wooseob Kim, Michael A. Paley, Monica M. Yang, A. Carvidi, Emanuel Demissie, Alia A. El-Qunni, Alem Haile, Katherine Huang, Baylee Kinnett, Mariel J. Liebeskind, Zhuoming Liu, L. McMorrow, D. Páez, Niti Pawar, D. Perantie, Rebecca E. Schriefer, Shannon E. Sides, Mahima Thapa, M. Gergely, Suha Abushamma, Sewuese Akuse, Michael K Klebert, Lynne M. Mitchell, D. Nix, J. Graf, K. Taylor, S. Chahin, M. Ciorba, P. Katz, M. Matloubian, Jane A. O’Halloran, R. Presti, Gregory F. Wu, S. Whelan, W. Buchser, L. Gensler, Mary C. Nakamura, A. Ellebedy, A. H. Kim   +39 more
semanticscholar   +1 more source